CN106074463A - Cannabidiol application in preparation treatment gouty arthritis medicine - Google Patents
Cannabidiol application in preparation treatment gouty arthritis medicine Download PDFInfo
- Publication number
- CN106074463A CN106074463A CN201610414430.7A CN201610414430A CN106074463A CN 106074463 A CN106074463 A CN 106074463A CN 201610414430 A CN201610414430 A CN 201610414430A CN 106074463 A CN106074463 A CN 106074463A
- Authority
- CN
- China
- Prior art keywords
- cannabidiol
- gouty arthritis
- medicine
- application
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses cannabidiol application in preparation treatment gouty arthritis medicine.Inventor finds that cannabidiol has the effect of creatinine, uric acid in hyperuricemia mice serum that significantly reduces first, prevents and treats hyperuricemia and occurs.The regulation body cell factor simultaneously, effective antiinflammatory, alleviate gouty arthritis symptom, gouty arthritis is had treatment and prevention effect.Present invention also offers the pharmaceutical preparation of cannabidiol treatment gouty arthritis and corresponding pharmaceutical dosage form thereof, with conventional preparation method, the medicine of the various different dosage forms used clinically can be formed in, easy to use.
Description
Technical field
The present invention relates to Fructus Cannabis extract cannabidiol new application in medical science, concretely relate to cannabidiol and exist
Application in preparation treatment gouty arthritis medicine.
Background technology
Gouty arthritis is the class disease that internal purine metabolic disturbance causes.Purine through a series of metabolic alterations,
The product ultimately formed is uric acid.Uric acid does not has what physiological function, under normal circumstances, the uric acid of internal generation in human body
2/3 is discharged by kidney, and 1/3 is discharged by large intestine.Internal uric acid is to constantly generate and draining, and therefore it maintains in blood
Certain concentration.In the synthesis and catabolic process of purine, there is the participation of multiple enzyme, owing to the birth defect metabolism of enzyme occurs
Disorder, makes the synthesis of uric acid increase or discharge and reduces, all can cause hyperuricemia.When serum Uric Acid Concentration is too high, uric acid is i.e.
It is deposited in joint, soft tissue, cartilage and kidney with the form of sodium salt.Urate crystals can be gulped down by mononuclear cell in articular cavity
Biting, activate NALP3 complex, NALP3 Yu ASC protein binding activates capase1, capase1 therewith is that a kind of IL-1 β converts
Enzyme, can shear IL-1 β precursor and be allowed to be formed activated IL-1 β, and then IL-1 β and IL-1 receptor complex is combined, and passes through
MyD88 starts the NF κ B insecondary inflammatory cytokine of triggering and transcribes, and ultimately results in inflammatory reaction, forms gouty arthritis.
As treatment the most thoroughly can cause arthroncus, deformity, stiff, periarticular ecchymosis, tuberosity.
Its side effect of specific medicament colchicine of clinical treatment acute gouty arthritis is relatively big at present, stomach easily occurs
The untoward reaction such as bowel symptoms, bone marrow depression, therefore, needs badly and develops a kind of specially good effect and the relatively small medicine of side effect.
Cannabidiol (CBD) is that a kind of nontoxic of extraction from Fructus Cannabis floral leaf can be used for medicine, cosmetics, health food
The aldehydes matter of high added value.At present, the developed country such as Israel, the U.S., Britain has done raw material with it and has developed multiple
Special effect medicine and cosmetics.CBD is the non-additive composition in Fructus Cannabis, THC can be hindered to affect nerve system of human body, and have
The pharmacologically active such as spasmolytic, anxiety, it is known that can serve as treating the diseases such as epilepsy, diabetes, hypoxic ischemic encephalopathy of newborn
The active component of sick medicine.
Summary of the invention
It is an object of the invention to provide the new application of cannabidiol, i.e. new opplication in pharmacy.
It practice, the present invention relates to cannabidiol application in the medicine of preparation treatment or prevention gouty arthritis.
The invention still further relates to cannabidiol application in preparation fall blood uric acid medicine.
The invention still further relates to cannabidiol application in preparation treatment or prevention antihyperuricemic disease drug.
In order to be more fully understood that the essence of the present invention, pharmacological evaluation and result with cannabidiol illustrate that it is in system below
New application in medicine field.
1, prepare cannabidiol, but cannabidiol used is not limited to following preparation method obtains.
Taking cannabis, leaf, fiber crops bran or three's mixture, after remove impurity, drying, pulverize, CO2 is super faces extraction, second after remove impurity
Alcohol re-dissolved, lysate is pentane eluting after chromatography, collects eluent, concentrating under reduced pressure, vacuum drying, pulverizes, obtain Fructus Cannabis
Diphenol.
2, take cannabidiol, add water for injection dissolve, add 2.0 ‰ activated carbons, stirring, filter, continue with 0.45 μm,
0.22 μm microporous filter membrane classified filtering, supplements water for injection, is sub-packed in cillin bottle, lyophilization, recharges high-purity nitrogen, add
Plug, gland, packaging, obtain cannabidiol injection.
3, the cannabidiol impact on induced rat gouty arthritis is observed with conventional pharmacological testing.
Choose body weight 180～220gWistar male rat 50, be randomly divided into 5 groups, often group 10, i.e. normal control
Group, model group, cannabidiol high, medium and low (60mg/kg, 30mg/kg, 15mg/kg) dosage group.Take the crystallization of 250mg Monosodium urate to add
0.9% chloride injection solution 45ml, then add 5ml Tween 80, heated and stirred, it is configured to 50 Monosodium urate injection suspension.Except normal
Outside group, remaining is respectively organized rat and all anaesthetizes with pentobarbital sodium, and dorsal position is fixed, and Rat Right Ankle lateral rear punctures, Xiang Guan
Joint intracavity injects 0.2ml Monosodium urate suspension, induces gouty arthritis model.Normal group intraarticular injection equal-volume physiology
Saline.Started to be administered cannabidiol injection, successive administration 6 days the same day in modeling.Within 7th day, stop being administered, adjoin in morning and take blood,
Centrifuging and taking serum, detects creatinine in serum, uric acid content.Rinse with 0.9% sodium chloride injection 0.5ml, it is thus achieved that animal suffers from knee joint
Joint irrigation, measure Inflammatory Factors Contents.
(1) take serum, detect creatinine in serum, uric acid content.
Table 1 cannabidiol is to creatinine, uric acid content and xanthine oxidase activity in gouty arthritis rat blood serum
Impact
Note: compared with model group,*P ＜ 0.01.
(2) take flushing liquor, detect flushing liquor IL-1 β, IL-6, PGE2 content.
The impact on gouty arthritis rat articular flushing liquor IL-1 β, IL-6, PGE2 content of table 2 cannabidiol
Note: compared with model group,*P ＜ 0.05.
Experimental result shows: cannabidiol can reduce creatinine, uric acid level in hyperuricemia mice serum, preventing and treating height
Hyperuricemia occurs.The regulation body cell factor simultaneously, effective antiinflammatory, alleviate gouty arthritis symptom.To gouty joint
Inflammation has preventive and therapeutic effect.
The invention provides with cannabidiol as active component, for treating the pharmaceutical preparation of gouty arthritis.This medicine
Thing preparation is with cannabidiol for effective active composition, and includes other adjuvant components acceptable on pharmaceutics.Described
Pharmaceutical preparation includes oral agents and injection, and wherein oral agents includes capsule, oral liquid, tablet, drop pill, granule etc., injection
Dosage form includes injection dosage form and freeze-dried powder injection type etc..When preparing oral formulations, available auxiliary type agent can be
The conventional filler such as starch, dextrin or cyclodextrin, sucrose, stearate.Lyophilized injectable powder can pass through aseptic spray drying, low
Prepared by the methods such as temperature vacuum drying, lyophilization.The later stage preparation technology of each preparation and equipment all belong to the conventional skill of pharmaceutical field
Art, this is not construed as limiting by the present invention, therefore not describes in detail at this.
Could be aware that from result above, it is an advantage of the current invention that:
1, known compound cannabidiol has been excavated new medical application by the present invention, has opened up a new application neck
Territory.
2, prove that cannabidiol can significantly reduce creatinine in hyperuricemia mice serum, uric acid water by serial experiment
Flat, prevent and treat hyperuricemia and occur.The regulation body cell factor simultaneously, effective antiinflammatory, alleviate gouty arthritis symptom.Fructus Cannabis
Diphenol has the effect significantly treating and preventing gouty arthritis.
3, the cannabidiol safety non-toxic of the present invention, pharmacological action is strong, imply that good prospect in medicine.
4, the present invention products material abundance, inexpensive, have no toxic and side effects, preparation technology is simple, and can make mouth
Oral dosage form, injection type, tablet etc., easy to use, injection can make intramuscular injection and intravenous injection.
Detailed description of the invention
Below by embodiment, the present invention is described in further detail, but embodiment is not to the technology of the present invention side
The restriction of case.
Embodiment 1
Taking cannabis, leaf, after remove impurity, drying, pulverize, CO2 is super faces extraction, ethanol re-dissolved after remove impurity, lysate warp
Pentane eluting after chromatography, collects eluent, concentrating under reduced pressure, vacuum drying, pulverizes, obtain cannabidiol.
Take cannabidiol 100 grams (crossing 80 mesh sieves), add 60 grams of microcrystalline Cellulose, cross 80 mesh sieve three times, mix homogeneously, spray
Enter 95% ethanol solution, soft material processed, cross 40 mesh sieves and pelletize, 60 DEG C of dry half an hour, be sub-packed in 3# capsule, plastic-aluminum combined bag
Dress, makes capsule.
Embodiment 2
Taking cannabis, leaf, the mixture of fiber crops bran, after remove impurity, drying, pulverize, CO2 is super faces extraction, and after remove impurity, ethanol is again
Dissolving, lysate is pentane eluting after chromatography, collects eluent, concentrating under reduced pressure, vacuum drying, pulverizes, obtain cannabidiol.
Take cannabidiol powder, admixture doses 5～the dried starch of 20% and 1～the magnesium stearate of 5%, blended, system
Grain, is dried, tabletting, makes tablet.
Embodiment 3
Repeat embodiment 2, have following difference: take cannabidiol powder, add sucrose water and the preservative of convention amount, surely
Determine the adjuvants such as agent.Filtration, sterilizing, be distributed in 10mL bottle, make oral liquid.
Embodiment 4
Repeat embodiment 2, have following difference: take cannabidiol powder, add water for injection and dissolve, add 2.0 ‰ and live
Property charcoal, stirring, filter, continue with 0.45 μm, 0.22 μm microporous filter membrane classified filtering, supplement water for injection, be sub-packed in cillin bottle
In, lyophilization, recharge high-purity nitrogen, jump a queue, gland, packaging, make injection.
Claims (3)
1. cannabidiol application in the medicine of preparation treatment or prevention gouty arthritis.
2. cannabidiol application in preparation fall blood uric acid medicine.
3. cannabidiol application in preparation treatment or prevention antihyperuricemic disease drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610414430.7A CN106074463A (en) | 2016-06-14 | 2016-06-14 | Cannabidiol application in preparation treatment gouty arthritis medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610414430.7A CN106074463A (en) | 2016-06-14 | 2016-06-14 | Cannabidiol application in preparation treatment gouty arthritis medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106074463A true CN106074463A (en) | 2016-11-09 |
Family
ID=57845610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610414430.7A Pending CN106074463A (en) | 2016-06-14 | 2016-06-14 | Cannabidiol application in preparation treatment gouty arthritis medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074463A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107126414A (en) * | 2017-03-22 | 2017-09-05 | 哈尔滨惠美佳生物科技有限公司 | Cannabidiol supensoid agent for treatment of arthritis and preparation method thereof |
| CN110064030A (en) * | 2019-05-30 | 2019-07-30 | 厦门梓素生物科技有限公司 | One kind extract for treating gouty arthritis medicinal application of CBD containing cannabidiol |
| CN110575432A (en) * | 2018-06-08 | 2019-12-17 | 汉义生物科技（北京）有限公司 | Composition containing cannabidiol and application of composition in animal products |
| CN112999212A (en) * | 2019-12-20 | 2021-06-22 | 烟台汉麻生物技术有限公司 | Application of cannabidiol-3-sulfonic acid in preparation of medicines for preventing and/or treating inflammation-related diseases |
| CN113197842A (en) * | 2021-04-19 | 2021-08-03 | 石家庄学院 | Cannabidiol injectable hydrogel, preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6949582B1 (en) * | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| WO2010126501A1 (en) * | 2009-04-29 | 2010-11-04 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
-
2016
- 2016-06-14 CN CN201610414430.7A patent/CN106074463A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6949582B1 (en) * | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
| WO2010126501A1 (en) * | 2009-04-29 | 2010-11-04 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
Non-Patent Citations (1)
| Title |
|---|
| 魏平等: "《临床速查掌中宝丛书-内分泌科临床速查掌中宝》", 31 January 2015, 军事医学科学出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107126414A (en) * | 2017-03-22 | 2017-09-05 | 哈尔滨惠美佳生物科技有限公司 | Cannabidiol supensoid agent for treatment of arthritis and preparation method thereof |
| CN110575432A (en) * | 2018-06-08 | 2019-12-17 | 汉义生物科技（北京）有限公司 | Composition containing cannabidiol and application of composition in animal products |
| CN110575432B (en) * | 2018-06-08 | 2021-10-12 | 汉义生物科技（北京）有限公司 | Composition containing cannabidiol and application of composition in animal products |
| CN110064030A (en) * | 2019-05-30 | 2019-07-30 | 厦门梓素生物科技有限公司 | One kind extract for treating gouty arthritis medicinal application of CBD containing cannabidiol |
| CN112999212A (en) * | 2019-12-20 | 2021-06-22 | 烟台汉麻生物技术有限公司 | Application of cannabidiol-3-sulfonic acid in preparation of medicines for preventing and/or treating inflammation-related diseases |
| CN113197842A (en) * | 2021-04-19 | 2021-08-03 | 石家庄学院 | Cannabidiol injectable hydrogel, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106074463A (en) | Cannabidiol application in preparation treatment gouty arthritis medicine | |
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN106074465A (en) | Cannabinol compounds application in preparation treatment gouty arthritis medicine | |
| CN106074493A (en) | The application in preparation treatment gouty arthritis medicine of a kind of Fructus Cannabis extract | |
| CN104739848A (en) | Composition containing L-arabinose and tagatose as well as preparation method and drug application of composition | |
| CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
| CN106074496A (en) | Cannabinol compounds application in preparation treatment gout medicine | |
| US20160303178A1 (en) | Pharmaceutical composition, method for preparing the same and use thereof | |
| CN101278928B (en) | Medicament composition containing levocarnitine or its derivatives and use thereof | |
| CN103083401B (en) | The compound medicament composition of a kind of Rhizoma Chuanxiong extract and Caulis Sinomenii extract composition | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN106074464A (en) | Cannabidiol application in preparation treatment gout medicine | |
| CN105998192A (en) | Application of industrial cannabinoid in preparing drugs for treating gouty arthritis | |
| CN114948980B (en) | Pharmaceutical composition for preventing and/or treating anxiety insomnia and application thereof | |
| CN1762341B (en) | Salvianolic acid compound for treating cardiovascular and cerebrovascular disease and liver disease, and application thereof | |
| CN101757443A (en) | Traditional Chinese medicine preparation for treating hemophilia | |
| CN105311044B (en) | A kind of pharmaceutical composition is as the application in preparation treatment cutaneous vasculitis drug | |
| CN101032534B (en) | Method of preparing Ilex rotunda Thunb total saponins and the application thereof | |
| CN103222966A (en) | Solid pharmaceutical composition containing Fingolimod hydrochloride and preparation method thereof | |
| CN102058714A (en) | Medicinal composition for treating hemophilia | |
| CN113384612A (en) | Anti-gout composition and preparation method and application thereof | |
| CN108542940A (en) | A kind of Chinese medicine composition prepare prevent and/or treatment hand-foot-and-mouth disease drug in application | |
| CN101190937B (en) | Compound with liver-protecting activity | |
| CN101991596B (en) | Application of oral medicine composition in preparation of medicines for preventing or treating coronary heart disease | |
| CN102813661A (en) | Novel application for glycyrrhetinic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Chenfeng Inventor after: Hu Chengyue Inventor before: Chen Tianrui Inventor before: Hu Chengyue |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |